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ABSTRACT
Aim The present review was performed in order to assess the 
effect of topical photodynamic therapy with 5-ALA in pre-
malignant lesions, using the Tsai’s protocol. 
Material and methods Studies, using the Tsai’s protocol with 
topical photodynamic therapy with 5-ALA, in  oral potentially 
malignant disorders (oral leukoplakia, oral eryhtroplakia, oral 
verrucous leukoplakia, oral lichen planus) and with at least 5 
months follow-up, were selected. The light source was: 635 nm 
laser light or LED red light at 635 nm. The main outcome measure 
was the healing of the potentially malignant disorders evaluated 
as  Complete Response, Partial Response, No Response.
Results Of the 12 eligible studies, five studies were included. 
Seven studies were excluded because they did not followe the 
Tsai’s protocol, 2 because the lesions were analyzed in other 
studies. The outcomes were: Oral Leucoplakia 7.7% complete 
response, 50.8% partial response, 41.5% no response; Oral 
Erythroplakia: 91,7% complete response, 8.3% partial response; 
Oral Verrucous Hyperplasia 100% complete response.
Conclusions Within the limitation of the present systematic 
review, the selected studies suggested that 5-ALA PDT, using 
the fractionated Tsai’s protocol, had good results in the 
treatment of  oral verrucous hyperplasia, less in erythroplakia 
and leukoplakia; this could be due to the different epithelial 
structure of the lesions. Further studies need to be conducted 
to confirm these data.
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INTRODUCTION
Oral potentially malignant disorders are a series of pathologies 
characterized by a risk of neoplastic degeneration superior 
than the normal mucosa. The most common are: leukoplakia, 
erythtroplakia, oral verrucous hyperplasia and oral lichen 
planus (1). The treatment for premalignant lesions in the 
oral cavity includes: observation, laser ablation, surgical 
resection, topical application of vitamin A or beta caro-
tene, photodynamic therapy (2-5). Photodynamic therapy 
(PDT) is a treatment that consists in the activation, by light, 
at a specific wave-lenght, of a photosensitizing agent in the 
presence of oxygen. The exposure of the photosensitizer to 
light results in the formation of oxygen molecules, causing 
localized photodamage and cell death. One advantage of 
PDT is that this technique can be applied repeatedly at the 
same site (6, 7). Several in vitro studies have demonstrated 
that PDT uses a cellular, vascular and immunological 
mechanism of destruction of the neoplastic tissue. In vitro, 
cell death occurs by a mithocondrial-dependent apoptosis 
(8-12). Usually the photosensitizer used for topical PDT on 
pre-malignant lesions is 5-aminolevulinic acid (5-ALA), 
which has been introduced for the therapy of cancer. 
It has a limited light penetration at 635 nm, so its use is 
restricted to superficial lesions (1-2 mm) (13). There are no 
evidence of the toxicity of 5-ALA before light exposure. 
After irradiation most patients report pruritus, prickling 
and burning sensation in the irradiated area (13). 
The aim of this systematic review is to assess the role of topical 
photodynamic therapy with 5-ALA, with the fractionated 
Tsai’s protocol, in the healing of oral potentially malignant 
disorders. This work has been performed according to the 
Preferred Reporting items for Systematic reviews and Meta-
Analyses (PRISMA) guidelines (14).
MATERIALS AND METHODS
This systematic review included RCTs, longitudinal 
studies, case series, case reports dealing with patients 
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or per os) and different PDT protocol were excluded 
as studies not published in English. Review articles, 
experimental studies, commentaries, letters to the Editor 
and unpublished articles were excluded.
The outcome measure was: 
- Healing of the lesion classified as: 
 • Complete response (CR): complete healing of the 
lesion;
 • Partial response (PR): reduction in size of the le-
sion;
 • No response (NR): no change in size of the lesion.
The healing was analyzed according to the different 
premalignant lesions.
Hand searching was performed from 1998 to 2016: 
• MEDLINE via OVID (December 1998-August 2016);
• EMBASE via OVID (December 1998-August 2016).
Key words used were:  Photodynamic therapy AND/
OR oral potentially malignant disorders, topical 
photodynamic therapy, photodynamic therapy with 
5-ALA, oral potentially malignant disorders
The most recent electronic search was undertaken on 
29/09/16.
Hand search was carried on the following journals: J 
Oral Pathol Med, Oral Oncology, Cancer, Lancet Lett, 
Lancet Oncol, J Dent Res, Head and Neck, Arch Oral Biol, 
Photochem Photobiol B, Photomed laser Surg, J Oral 
Pathol Med, Laser Surg Med, Int J Oral Maxillofac Surg, J 
Oral Pathol Med, Oral Oncol, Laser Surg Med, J Oral Pathol 
Med, Arch Otolaryngol Head Neck Surg, Annal Stomatol, 
Oral Oncol, Laser Surg Med, Photodiagnosis Photodyn Ther.
that had Topical-PDT for pre-malignant lesions, i.e. oral 
verrucous hyperplasia (OVH), oral leukoplakia (OL), oral 
erythroplakia (OEL), and oral lichen planus (OLP). Clinical 
diagnosis of the selected patients should be confirmed by 
histopathological examination of the biopsy specimens; 
smokers, areca chewers and drinkers were included.
The same type of intervention was considered as 
described: Topical photodynamic therapy should be 
applied with light source 635 nm laser light or led light at 
635 nm, once a week, according to Tsai protocol (15): five 
3-minute and one 100-second irradiations, separated by 
five 3-minute rests for a total of 1000 seconds (fluence 
rate, 100mW7cm2; light exposure dose, 100 J/cm2) (Table 
1, 2), with 5-ALA (20% ALA gel form) as photosensitizer. 
Studies to be included had to have a minimum of 
5-months follow-up.
All studies to be included had to report the following.
1) The healing of the lesions as:
 • Complete response (CR): complete healing of the 
lesion;
 • Partial response (PR): reduction in size of the le-
sion;
 • No response (NR): no change in size of the lesion.
2) Clinical features of the lesions (OL, OVH, OEL, OLP).
If possible the grade of dysplasia of the lesions (no 
dysplasia, mild dysplasia, moderate dysplasia, severe 
dysplasia, carcinoma in situ) had to be evaluated in 
connection with the healing of the lesion.
All studies with a different photosensitizer, different 
use of photosensitizer (e.g. intravenous, intra-muscle 











Lin 2010 Arts International 
Biotechnology
Inc. Tapei Taiwan
635 nm 0-1200 mW 100mW/cm2 fractionated 
protocol tot 
1000 sec
100J/cm2 40 OVH 
40 OEL
TABLE 1 Summary of laser parameters and lesion treated.
First author Year Center Wavelenght Irradiance at target Energy density per point Exposure duration Lesion
Yu 2009 635±5 100mW/cm2 100 J/cm2 multiple180 sec. irradiation 
several 180 sec rest  
tot 1000 sec
20 OEL
Yu 2008 635±5 100mW/cm2 100 J/cm2 multiple180 sec. irradiation 
several 180 sec rest  
tot 1000 sec
36 OVH
Chen 2007 635±5 100mW/cm2 100 J/cm2 multiple180 sec. irradiation 




Chen 2004 635±5 100mW/cm2 100 J/cm2 multiple180 sec. irradiation 
several 180 sec rest  
tot 1000 sec
5 OVH
TABLE 2 Summary of LED red light parameters and lesions treated.
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INCLUDED STUDIES
Author/Year Partecipants Intervention Outcome
Lin 2010 All patients affected by OVH (40 patients, 
39 men and one woman, aged 42-74 years) 
or OEL(40 patients, 38 men and 2 women, 
aged 34-89 years). Pa-tients were treated in 
the Department oOf Oral and Maxillofacial 
Surgery, National Taiwan University Hospital 
(NTUH) from August 2006 to February 2010 
Topical PDT with 5-ALA, 
according to Tsai’s 
protocol, once a week. 
635 nm laser light. Mean 
follow-up 20 months for 
OVH, 18 months for OEL
Healing of OVH and 
OEL characterized by 
complete response (CR), 
partial response (PR), no 
response (NR) Grade of 
dysplasia
Yu 2009 All patients affected by OEL. We selected 
only 20 patients tretated with LED light, 
because the other are included in further 
studies. Patients were treated in the 
Department of Oral and Maxillofacial 
Surgery, National Taiwan University Hospital 
(NTUH) from January 2002 to April 2009
Topical PDT with 5-ALA, 
according to Tsai’s pro-
tocol, once a week. 635 
LED light. Mean follow-
up 32 months
Healing of OEL 
characterized by complete 
response (CR), partial 
response (PR), no 
response (NR) Grade of 
dysplasia
Yu 2008 All patients affected by OVH (36 patients, 
35 men and one women, aged 32-79 years). 
Patients were treated in the Department of 
Oral and Maxillofacial Sur-gery, National 
Taiwan University Hospital (NTUH) from July 
2002 to December 2006
Topical PDT with 5-ALA, 
according to Tsai’s pro-
tocol, once a week. 635 
LED light. Mean follow-
up 26 months
Healing of OVH 
characterized by complete 
response (CR), partial 
response (PR), no 
response (NR) Grade of 
dysplasia
Chen 2007 All patients affected by OVH (24 male 
patients, aged 32-79 years), OL (65 
patients, aged 26-77 years) and OEL (6 
male patients). Patients were treated in 
the Department of Oral and Maxillofacial 
Surgery, National Taiwan University Hospital 
(NTUH) from November 2001 to December 
2005
Topical PDT with 5-ALA, 
according to Tsai’s pro-
tocol, once a week. 635 
LED light. Mean follow-
up 22,2 months
Healing of OVH, OL, 
OEL characterized by 
complete response (CR), 
partial response (PR), no 
response (NR) Grade of 
dysplasia
Chen 2004 All patients affected by OVH (5 male 
patients, aged 37-64 years). Patients were 
treated in the Department of Oral and 
Maxillofacial Surgery, National Taiwan 
University Hospital (NTUH) from 2002 to 
2003
Topical PDT with 5-ALA, 
according to Tsai’s pro-
tocol, once a week. 635 
LED light. Mean folow-up 
5.6 months
Healing of OVH 
characterized by complete 
response (CR), partial 




Author/Year Reason for exclusion
Maloth 2016 The light source was a light emitting diode with a different wavelength (420 nm)
Romeo 2014 Topical PDT performed twice a week
Sharfistein 
2011
Use of a dye laser in pulse at 585 nm, at intervals of 1 to 3 seconds
Chen 2005 Topical PDT performed twice a week for OL and patients with OVH were enrolled in further studies
Sai 2004 Patients of this studies are enrolled in further studies
Sieron 2003 PDT protocol is not described
Kubler 1998 Topical PDT is performed without the fractionated protocol
TABLE 3 Included and excluded studies.
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The references of the selected articles were analyzed to 
find other relevant studies.
The patient who had Topical-PDT for pre-malignant 
lesions (oral leukoplakia, oral erythroplakia, oral 
verrucous leukoplakia, oral lichen planus) was considered 
as unit of analysis.
The data were analyzed as percentage of the healing 
of the lesion evaluated as: CR, PR, NR in relation to the 
number of patient treated.
 
RESULTS
Of the 12 potentially eligible studies, seven studies had to 
be excluded (Kubler, 1998; Sieron, 2003; Tsai, 2004; Chen 
2005; Sharfistein, 2011; Romeo, 2014; Maloth, 2016) 
(15-21) because: in 3 studies the author did not apply 
the fractionated protocol (Kubler, 1998; Sieron, 2003; 
Sharfistein, 2011); in 2 studies the lesions were included 
in further studies (Tsai, 2004; Chen, 2005); in one study 
topical PDT was applied twice a week (Romeo, 2014) and 
in one study the light source was a light emitting diode 
with a different wavelengh (420 nm) (Maloth, 2016). The 
five studies included were: Chen, 2004; Chen,  2007; Yu, 
2008; Yu, 2009; Lin, 2010 (22-26) (Table 3).
The study of Chen (2007) and the study of Lin (2010) 
are repeated in the analysis because they treated two 
different types of lesions (Oral Erythroplakia and Oral 
Verrucous Hyperplasia).
1) Healing of Oral Leukoplakia (OL): 1 study (Chen 2007), 
65 patients.
 • Chen (2007) studied 97 OL, of these we selected 
only 65 treated once a week. The mean follow-up 
was of 22.2 (range 3-34) months. The grade of 
dysplasia was not indicated. 5 lesions showed CR, 
33 PR and 27 NR. The 5 OL required an average of 
3.8 (range 1-7) treatments of ALA-PDT to achie-
ve CR of the lesions. One of the five CR patients 
lesions recurred 6 months after the first PDT and 
finally was excised by surgery. The remaining four 
lesions with CR showed no recurrence after a 
follow-up period of 3-36 months (mean 24.3). Of 
the 33 PR patients, 8 received further treatment 
with topical ALA-PDT once a week, 2 received 
further treatment with topical ALA-PDT twice a 
week, 4 chose total excision of the lesion and the 
remaining 19 chose a follow-up schedule once a 
month. Of the 27 NR patients, 6 received further 
treatment with topical ALA-PDT once a week, 5 
received further treatment with topical ALA-PDT 
twice a week, 10 chose total excision of the lesion 
and the remaining 6 chose the follow-up once a 
month. 
2) Healing of Oral Erythroplakia (OEL): two studies (Yu 
2009; Lin 2010),  60 patients.
 • Yu (2009) selected 46 patients with OEL and he 
treated 20 lesions with LED light and 26 lesions 
with laser light; in our review we selected only 
the 20 OEL lesions treated with LED light becau-
se the other lesions are included in another study 
(Lin, 2010). The mean follow-up was of 32 (ran-
ge 16-76) months. Of the 20 lesions, 4 had mild 
dysplasia, 12 had moderate dysplasia, 3 had se-
vere dysplasia and 1 was a carcinoma in situ. The 
lesions showed CR in 17 and PR in 3 cases. The 17 
CR OEL lesions needed an average of 3.7 (range 
2-7) treatments of ALA-PDT to achieve CR. After 
a follow-up period of 16-76 (mean 32) months, 
5 (29%) of the 17 CR lesions recurred. The five 
lesions recurred 8-14 (mean 11) months after the 
last PDT treatment. The five recurrent lesions were 
treated by the same PDT protocol as before and 
showed complete regression after 2-4 (mean 2.8) 
treatments.
 • Lin (2010) selected 40 patients with OEL. The 
mean follow-up was of 18 (range 6-30) months. 
Twelve lesions had mild dysplasia, 18 had mode-
rate dysplasia, seven had severe dysplasia and 3 
were carcinoma in situ. The 40 OEL showed a CR 
in 38 and PR in two. The 38 CR OEL lesions re-
quired an average of 3.4 (range 2-6) treatments 
of ALA-PDT to achieve CR of the lesions. During 
the follow-up period eight (21%) of the 38 CR 
OEL lesions recurred. These eight OEL lesions re-
curred 6-14 (mean 9) months after the last PDT 
treatment. The eight OEL recurrent lesions were 
treated by the same PDT protocol as before and 
showed complete regression after 1-3 (mean 2) 
months.
3) Healing of Oral Verrucous Hyperplasia (OVH): 4 
studies   (Chen 2004; Chen 2007; Yu 2008; Lin 2010), 
105 patients.
 • Chen (2004) studied the treatment of five pa-
tients. The mean follow-up was of 5,6 (range 
3-11) months. Any lesions had dysplasia. An ave-
rage of two treatments (range 1-3 treatments) of 
ALA-PDT were needed to achieve the complete 
regression of the lesion. No recurrence was found 
after a follow up period of 3-11 months (mean 5.6 
months). 
 • Chen (2007) studied 24 OVH. The mean follow-up 
was 15,2 (range 3-42) months.; 20 lesions had no 
dysplasia, 2 lesions had mild dysplasia, one had 
moderate dysplasia and one had severe dysplasia. 
All the 24 OVH lesions showed CR after an avera-
ge of 3.5 (range, 1-6) treatments of ALA-PDT. No 
recurrence of the 24 OVH lesions was found after 
a follow-up period of 3-42 (mean 1.2) months.
 • Yu (2008) studied 36 OVH. The mean follow-up 
was 26 (range 6-56) months. Biopsy was not done 
in one patient because the lesion was too small; 
the other 35 lesions: 26 had no dysplasia, 2 mild 
dysplasia, 4 moderate dysplasia, 3 severe dyspla-
sia. All the lesions showed CR after an average of 
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3.8 (range 1-6) treatments of PDT. No recurrence 
of the 36 OVH lesions was found after a follow-up 
period of 6-56 (mean 26) months. 
 • Lin (2010) studied 40 OVH lesions.  The mean fol-
low-up 20 (range 8-37) months; 25 lesions had 
no dysplasia, 9 has mild dysplasia, 4 had moderate 
dysplasia and 2 had severe dysplasia. All 40 OVH 
lesions showed CR after an average of 3.6 (range 
1-6) treatments of ALA-PDT. No recurrence of the 
40 OVH lesions was found after a follow up period 
of 8-37 (mean 20) months. 
Statistical analysis 
1) Healing (Table 4-5).
 • Oral Leukoplakia: one study, so meta-analysis 
could not be done. Total patients 65; CR was 
obtained in 5 patients (7.7%), PR in 33 patients 
(50.8%) and NR in 27 patients (41.5%).
 • Oral Erythroplakia: Total patients 60 (2 studies); 
CR was obtained in 55 patients (91.7%); PR in 5 
patients (8.3%); NR 0 patients.
Author Lesion Grade of dyspla-sia Patients Response
Chen (2004) OVH No dysplasia 5 CR 5
Chen (2007)
OVH
20 no  
2 mild  




CR 5  
PR 33  
NR 27
Yu (2008) OVH
26 no  
2 mild  




4 mild  
12 moderate  
3 severe  
1 ca in situ
20 CR 17 PR 3
Lin (2010)
OVH
25 no  
9 mild  




12 mild  
18 moderate  
7 severe  
3 ca in situ
40 CR 38 PR 2
TABLE 4 Healing of the lesions and histopathological datas ( OVH = Oral verrucouse Hyperplasia, OL = Oral Leukoplakia, OEL = Oral Erytroplakia, CR = 
Complete Response, PR =Partial Response, NR = No Response).
Lesion Author Total number of lesions Response




OEL Yu 2009  Lin 2010 60
CR 55 (91,7%)






105 CR 105 (100%)
 
TABLE 5 Healing of the lesions and clinical features.
 • Oral Verrucous Hyperplasia: Total patients 105 (4 
studies). CR was obtained in 105 patients (100%). 
The 100% CR was independent from the grade of 
dysplasia.
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2) Mean follow–up.
 • Oral Leukoplakia: 22.2 (range 3-34) months 
(Chen, 2007).
 • Oral Erythroplakia: 32 (range 16-76) months (Yu, 
2009); 18 (range 6-30) months (Lin, 2010).
 • OVH 5.6 (range 3-11) months (Chen, 2004); 15.2 
(range 3-42) months (Chen; 2007); 26 (range 
6-56) months (Yu, 2008); 20 (range 8-37) months 
(Lin, 2010).
3) Recurrence.
 • Oral Leukoplakia: 1 study of the 5 CR OL 1 recur-
red 6 months after the last treatment (20%).
 • Oral Erythroplakia: two studies Yu (2009), after a 
follow-up of 8-14 (mean 11) months, 5 of the 17 
CR OEL lesions recurred (29%); Lin (2010), after a 
follow-up of 6-30 (mean 18) months, 8 of the 38 
(21%) CR OEL lesions recurred.
 • Oral Verrucous Hyperplasia, four studies, no re-
currence Chen (2004) after a follow up of 5.6 
(range 3-11) months; Chen (2007) after a follow 
up of 15.2 (range 3-42) months; Yu (2008) after 
follow up of 26 (range 6-56); Lin (2010) after a 
follow up of 20 (range 8-37) months.
Number of treatments
• Oral Leukoplakia average of 3.8 treatments (range 1-7) 
to achieve CR of the lesions.
• Oral Erythroplakia  Lin (2010) average of 3.4 treatments 
(range 2-6); Yu (2009) average of 3.7 treatments (range 
2-7).
• Oral Verrucous Hyperplasia Lin (2010) average 3.6 
treatments (range 1-6); Yu (2008) average treatment 
3.8 (range 1-6); Chen (2007) average treatments 3.5 
(range 1-6); Chen (2004) average treatments 2 (range 
1-3).
DISCUSSION
The WHO Collaboration Centre well defined the 
pre-malignant lesions, describing them as “clinical 
presentations that may have a potential to become 
cancer” (1). Malignant transformation may occur in 
a limited, but not negligible, rate of patients, so early 
therapy is preferable to avoid further complications. 
One of the therapy proposed was topical photodynamic 
therapy.
The present review showed that topical photodynamic 
therapy with 5-ALA PDT applied once a week obtained 
resolution of the lesions treated in all the cases of Oral 
Verrucous Hyperplasia, in almost 90% of Oral Erytroplakia 
lesions and in less than 10% of Oral Leukoplakia. We 
found only one study that compared the healing of Oral 
lichen planus with PDT or with conventional therapies. We 
excluded this study because the LED light source applied 
was different from the one used in the Tsai protocol 
(21). No comparative studies about the treatment of OL, 
OEL and OVH with PDT versus conventional therapies 
were found, so it was not possible to determine which 
can be the best therapy for pre-malignant oral lesions. 
Even if Topical Photodynamic therapy seems promising, 
simple to use and with limited side effects, few studies 
were conducted on this topic. Topically PDT has a good 
response in the treatment of OVH, as reported in this 
review. If different studies use different protocols, they 
are difficult to analyze and it becomes difficult for the 
clinician to chose a specific treatment regimen. So we 
select the use of PDT applied once a week  with LED light 
or laser light.  According to the literature (25) the therapy 
could be conducted either with LED light or laser light. In 
fact, the total light dose is important for a successful PDT 
outcome, despite of the light source. At the end of the 
selection process, only 5 studies could be included out of 
twelve; five were excluded because they did not adhere 
to the chosen protocol. 
The number of participants of each study was small and 
we didn’t find any trial, for that reason a meta-analysis 
has been impossible to conduct. 
From data analysis the healing of OVH showed to be better 
than the healing of OEL, while OL had scarse response to 
the therapy. This could be due to a different structure of 
the lesions, since OVH has a rough surface which is able 
to hold more drug. According to Yu (2008), OVH lesion 
provided a large area of good retention and absorption 
of ALA on the surface. For OVH lesions the grade of 
dysplasia did not influence the response to the therapy, 
but it was strictly connected with the mean number of 
treatments (24). We have to consider that this conclusion 
is based on only one study on OL with 65 lesions treated, 
while we have 2 studies (60 patients) and 4 studies (105 
patients) on OEL and OVH respectively.
Another important aspect is the recurrence of the lesions. 
No recurrence was found in OVH, while in OL lesions 20% 
recurred at 6 months follow-up; in OEL lesions, according 
to Yu (2009) (25) 29% recurred after a follow-up period 
of 8-14 months and according to Lin (2010) (26) 21% 
after a follow-up of 6-30 months.
According to Lin 2010 (26), Yu 2008 (24), Yu 2009 (25) 
correlation analysis found that the mean treatment 
number of PDT to achieve a CR for OVH lesions and 
OEL lesions is strictly correlated to diameter, clinical 
appearence, color, epithelial dysplasia and surface 
keratine layer. In general, lesions with smaller size, pink to 
red color, epithelial dysplasia and thinner surface keratin 
layer had better PDT outcomes.
Another recent review analyzed the treatment of pre-
malignant lesions with PDT (27). They concluded that in 
general PDT is effective in the management of premalig-
nant lesions. Different therapies and different protocols 
were included so results ranged from 27-100% complete 
resolution, 5-50% partial resolution and 0-25% no reso-
lutions of the lesions, with a recurrence rate of 36%. No 
comparative study was considered, so it was not possible 
to understand which the best treatment could be. Be-
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sides, it is difficult to draw conclusions when different 
protocols are applied on few patients, so the present re-
view was concentrated on a specific treatment protocol 
and comparison with the previous one was not possible. 
More studies are advisable comparing in a randomized 
way different protocols, so that the best treatment could 
be selected for the patient. 
CONCLUSION
Within the limitation of the present systematic review 
the analysis of the clinical data of the selected studies 
suggests that 5-ALA PDT, using the fractionated Tsai’s 
protocol, either with laser light or red LED light, is 
very effective in the treatment of the oral verrucous 
hyperplasia, less in erythroplakia and leukoplakia; this 
could be due to the different epithelial structure of the 
lesions. Further studies should be conducted to confirm 
this data and add more power to the findings. 
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